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injury and inflammation by normalizing 
muscular mitochondrial function associated 
with a nitric oxide protective mechanism 
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Abstract 
Background: Crush syndrome (CS) is a serious medical condition characterized by muscle cell damage resulting 
from decompression after compression (i.e., ischemia/reperfusion injury). A large number of CS patients develop 
cardiac failure, kidney dysfunction, and systemic inflammation, even when fluid therapy is administered. We evalu-
ated whether the administration of astragaloside-IV (AS)-containing fluid improved survival by preventing kidney and 
muscular mitochondrial dysfunction in a rat model of CS.
Results: The CS model was generated by subjecting anesthetized rats to bilateral hind limb compression with a 
rubber tourniquet for 5 h. Rats were then randomly divided into four groups: (1) sham; (2) CS with no treatment; (3) 
CS with normal saline treatment; and (4) CS with normal saline + 10 mg/kg AS. AS-containing fluid improved kidney 
function by improving shock and metabolic acidosis in CS rats. In addition, there was a reduction in oxidative damage. 
The attenuation of hyperkalemia was significantly related to improving muscle injury via preventing mitochondrial 
dysfunction. Moreover, this mitochondria protection mechanism was related to the nitric oxide (NO) generated by 
activation of endothelial nitric oxide synthase, which provided an anti-oxidative and anti-inflammatory effect.
Conclusions: Treatment with AS-containing fluid led to a dramatic improvement in survival following CS because of 
direct and indirect anti-oxidative effects in the kidney, and improvements in mitochondrial dysfunction and inflam-
mation owing to AS acting as an NO donor in injured muscle.
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Background
Crush syndrome (CS) is a serious medical condition 
characterized by circulatory shock, acute kidney injury 
(AKI), and systemic inflammation that occurs after 
traumatic events such as earthquakes, landslides, and 
traffic accidents [1]. It is associated with a high mortal-
ity rate, especially in the acute phase. CS develops after 
decompression of limb muscles (reperfusion) following 
prolonged compression (ischemia) of a large portion of 
skeletal muscle, resulting in rhabdomyolysis (muscle cell 
breakdown). However, in addition to its local effects, CS 
can cause systemic failure resulting from acute respira-
tory distress syndrome (ARDS), systemic inflammatory 
response syndrome (SIRS), multiple organ failure, and 
confounding late-phase symptoms [2].
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Fluid therapy is the first-line treatment for CS. Shock 
and acute kidney failure can be prevented by early infu-
sion of fluid. Electrolyte abnormalities are common in 
patients with crush-related acute kidney failure, and fatal 
hyperkalemia is the most severe abnormality, for which 
treatment with normal saline containing sodium bicar-
bonate is recommended [3]. In the clinical setting, fluid 
resuscitation therapy is beneficial for early symptoms; 
however, it is difficult to prevent an inflammatory con-
dition from developing after an ischemia/reperfusion 
injury (IRI).
Astragaloside-IV (3-O-beta-d-xylopyranosyl-6-O-beta-
d-glucopyranosyl-cycloastragenol, AS), isolated from 
Astragalus membranaceus, is a bioactive saponin of astra-
galosides. Accumulating evidence has demonstrated the 
anti-inflammatory effects of AS against mitochondrial 
damage [4, 5] and its anti-oxidative effects [6, 7]. In addi-
tion, AS has been shown to protect against acute kidney 
injury [8] and kidney tubular injury [9], which is impor-
tant for CS therapy. These effects of AS are believed to 
involve nitric oxide (NO), because they are consistent 
with previously demonstrated benefits of NO generation 
via endothelial nitric oxide synthase (eNOS). This mecha-
nism early after decompression prevents muscle dam-
age induced by ischemia/reperfusion via the protective 
effects of NO and the suppression of systemic inflam-
mation, thereby increasing survival rates in CS [10, 11]. 
AS therapy has been proposed as an early intervention to 
treat CS in the clinic. However, few studies have focused 
on these mechanisms of AS. Therefore, we hypothesize 
that treatment with AS inhibits mitochondrial dysfunc-
tion via an eNOS activation mechanism in injured mus-
cle in CS model rats, and the experiments presented 
herein are designed to test that hypothesis.
Methods
Animal model of CS
Male Wistar rats weighing 250–300  g were obtained 
from Japan SLC (Shizuoka, Japan) and housed in a room 
maintained at a temperature of 23 ± 3  °C and a relative 
humidity of 55 ±  15% under a 12:12-h light/dark cycle, 
with free access to food and water. Animal experiments 
were carried out according to the guidelines for animal 
use and approved by the Life Science Research Center of 
Josai University (approval nos. H26027, H26028, H27025, 
and H27027). Anesthesia was induced by intraperito-
neal injection of sodium pentobarbital (50  mg/kg body 
weight). Body temperature was maintained throughout 
the experiment using a heating pad. The CS model was 
established as previously reported [12]. Briefly, a rubber 
tourniquet was applied to the bilateral hind limb of each 
rat, wrapped five times around a 2.0  kg metal cylinder, 
and the end of the band was glued. After a compression 
of 5 h, the compression was released by cutting the band 
and removing the tourniquet.
AS preparation
The chemical structure of AS (Carbosynth, Compton, 
UK) is depicted in Additional file  1: Fig. S1. The prob-
able purity of AS was 99.6 ± 0.8%, as determined using 
the partial modification HPLC method (HPLC condi-
tions: mobile phase: 50% acetonitrile, flow rate: 1.0 mL/
min, column: Inertsil-ODS3 (4.6  mm  ×  250  mm, φ 
5 μm), column temperature: 40 °C, detector wavelength: 
203  nm) [13]. A 1,1-diphenyl-2-picrylhydrazyl (DPPH) 
antioxidant assay of AS was performed as Sharma et al. 
[14] previously reported. Ascorbic acid (AA) has a high 
antioxidant capacity and was used as an antioxidant ref-
erence for comparison with AS.
Experimental design
Experimental-1 (AS dosage study) The AS dosages 
were selected using previous reports by Li et  al. [15] 
to determine the effective dosage in CS rats. To deter-
mine the optimal dose of AS, animals were randomly 
divided into seven groups: (1) sham; (2) CS with no 
treatment (CS-only group); and (3–7) CS with treat-
ment at 1, 2, 5, 10, and 20 mg/kg AS (named C-1, 2, 
5, 10, and 20 AS-one group, respectively) via tail vein 
bolus injection at decompression just before from a 
rubber tourniquet.
Experimental-2 (therapy effect study) To examine the 
effects of AS in CS, animals were randomly divided 
into four groups: (8) sham; (9) CS with no treatment 
(CS-only group); (10) CS with normal saline treat-
ment (C-saline group); and (11) CS with normal 
saline + 10 mg/kg AS (C-AS group). The C-saline and 
C-AS groups were subjected to decompression with 
the rubber tourniquet, immediately followed by 3 h of 
reperfusion by massive fluid resuscitation at a rate of 
30 mL/(kg h−1).
Experimental-3 (pharmacokinetics (PK) study) We ana-
lyzed the blood concentration profile and PK param-
eters of AS administered by tail vein to sham and CS 
rats. Animals were randomly assigned to four groups: 
sham, sham-AS, CS-only, and C-AS groups.
Analysis of mean arterial pressure (MAP), blood gas 
levels, biochemical parameters, coagulation, and NO 
and cytokine levels
MAP was recorded using a PowerLab data acquisition 
system (AD Instruments, Nagoya, Japan). One carotid 
artery was cannulated with a polyethylene catheter (PE-
50 tubing) connected to a pressure transducer. Arterial 
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blood samples from each group were obtained 1, 3, 6, and 
24 h after reperfusion using a carotid artery catheter. The 
pH, partial pressure of oxygen (PaO2), partial pressure of 
carbon dioxide (PaCO2), bicarbonate  (HCO3−) concen-
tration, and base excess of arterial blood were analyzed 
using an i-STAT300F blood gas analyzer (FUSO Pharma-
ceutical Industries, Osaka, Japan).
In each experimental group (0, 1, 3, 6, and 24  h after 
reperfusion, n  =  3–6), venous blood and tissue sam-
ples from the gastrocnemius muscles and kidneys were 
assayed for thiobarbituric acid reactive substances 
(TBARS), myeloperoxidase (MPO) activity, skeletal mus-
cle edema index, mitochondrial permeability transition 
(MPT), superoxide dismutase (SOD) activity, Western 
blotting, and histology at each time point. For histol-
ogy, tissues were fixed in 10% formalin and embedded in 
paraffin wax. Sections were cut and stained with hema-
toxylin and eosin and then carefully examined micro-
scopically. Venous blood samples from each group were 
obtained using a jugular catheter. Venous blood from 
the jugular vein was collected and centrifuged to meas-
ure plasma levels of potassium  (K+), blood urea nitrogen 
(BUN), creatinine (Cre), and creatine phosphokinase 
(CPK) (measurements were carried out by SRL Inc., 
Tokyo, Japan). Red blood cells (RBC), white blood cells 
(WBC), and platelets were measured using a Celltac 
hematology analyzer (Nihon Kohden Co., Tokyo, Japan). 
The nitrite  (NO2−) and nitrate  (NO3−) concentrations 
in muscle and plasma were measured using a dedicated 
HPLC system (ENO-20, Eicom, Kyoto, Japan), accord-
ing to a previously reported method [16]. Interleukin-1 
beta (IL-1β) and tumor necrosis factor alpha (TNF-α) 
were measured by ELISA according to the manufacturer’s 
instructions (Rat IL-1β/IL-1F2 Quantikine ELISA Kit and 
Rat TNF-α Quantikine ELISA Kit, R&D Systems, Inc., 
MN, USA).
Assessment of kidney function
The bladder was cannulated with PE-50 tubing concomi-
tantly with the jugular vein. Urine samples were obtained 
starting 1  h prior to decompression until immediately 
after decompression (0 h). Urine samples were then col-
lected every 1 h for 24 h and centrifuged at 1500×g for 
5  min at 20–25  °C. Kidney function was determined 
based on glomerular filtration rate (GFR), urine vol-
ume, urine osmotic pressure (Osmomat 030-D; Gonotec 
GmbH, Berlin, Germany), N-acetyl-β-d-glucosaminidase 
(NAG) levels (Shionogi & Co., Osaka, Japan), and urine 
pH (Pretest 5bII; Wako Pure Chemical Industries, Tokyo, 
Japan). Kidney injury marker-1 (KIM-1) was measured by 
ELISA according to the manufacturer’s instructions (Rat 
TIM-1/KIM-1/HAVCR Immunoassay, R&D Systems, 
Inc.).
Determination of reactive oxygen species (ROS) 
production, MPO activity, and mitochondrial function
ROS production in the injured gastrocnemius mus-
cle was determined by measuring the concentration of 
TBARS. MPO activity in the blood and muscle tissue 
was measured as previously described [10]. The rela-
tive weight (g/100 g body weight) of the injured muscle 
(gastrocnemius muscle) was determined, which acted as 
an index of skeletal muscle edema in the affected limbs. 
Isolation of mitochondria for evaluation of mitochon-
drial function in crush injury muscle was performed 
using a mitochondrial isolation kit for tissue (Thermo 
Fisher Scientific K.K., Kanagawa, Japan). In the MPT, 
mitochondrial membrane potential (i.e., mitochondrial 
inner membrane function) was evaluated using a JC-1 
mitochondrial membrane potential assay kit (Cayman 
Chemical Company, Ann Arbor, MI, USA). To evaluate 
mitochondrial outer membrane function, cytochrome c 
(cyt c) of crush injured muscle cytoplasm (in the samples 
that did not include mitochondria) was quantified using 
a  Quantikine® cyt c Immunoassay (R&D Systems, Inc.). 
SOD activity was determined using a SOD Assay Kit—
WST (Dojindo Laboratories, Tokyo, Japan). All operation 
procedures were performed in accordance with the cor-
responding instruction manuals.
Western blotting
Western blotting was carried out as previously described 
[10]. Briefly, rat muscle and kidney tissue were homog-
enized and centrifuged, and proteins in the lysate were 
separated by sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis. Proteins were detected on mem-
branes using antibodies against eNOS (Cell Signaling 
Technology, Tokyo, Japan), phospho-eNOS (Ser1177) 
(p-eNOS; Cell Signaling Technology), inducible NO syn-
thase (iNOS; Cell Signaling Technology), heme oxyge-
nase (HO)-1 (Thermo Fisher Scientific K.K.), α-tubulin 
(Cell Signaling Technology), and hypoxia-inducible fac-
tor-1 alpha (HIF-1α) (Abcam PLC, Tokyo, Japan). Protein 
bands were visualized using an enhanced chemilumines-
cence detection system (SuperSignal West Dura Extended 
Duration Substrate; Pierce Biotechnology, Tokyo, Japan) 
with horseradish peroxidase-conjugated secondary anti-
bodies (Pierce Biotechnology). Band intensities were 
quantified using a ChemiDoc XRS +  Molecular Imager 
with Image Lab software (Bio-Rad Laboratories, Hercu-
les, CA, USA), with α-tubulin used as a loading control.
Sampling and sample preparation for PK parameters
Blood samples from each group were obtained 0 (just 
before administration), 0.083, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 
3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 9, and 24 h after reperfusion via 
a jugular catheter. Sample preparations were optimized 
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as follows: 150 µL of plasma and urine samples were 
extracted with 150  µL methanol. These samples were 
vortexed and centrifuged at 12,000×g for 20 min at 4 °C. 
Two hundred microliters of the supernatant was mixed 
with 790 μL water and 10 μL 0.05 µg/mL digoxin (DIG, 
internal standard (IS), Wako Pure Chemical Industries, 
Ltd.), and these samples were subjected to cleanup on 
an active Strata™ X solid phase extraction column (Shi-
madzu GLC Ltd., Tokyo, Japan).
Instrumental and conditions for PK parameters of AS
AS concentrations were measured using LC–MS/
MS methods with an ACQUITY UPLC TQD (Waters, 
Milford, MA, USA). Masslynx 4.1 software was 
used for instrumental control, and acquisition and 
processing of the data. UPLC separation was per-
formed using an ACQUITY UPLC BEH C18 1.7  µm 
2.1  ×  100  mm column (Waters) kept at 40  °C. An MS 
detector with an electrospray ionization (ESI) inter-
face in negative ion mode  (ESI−) was used for quan-
titative analysis, with acquisition in multiple reaction 
monitoring (MRM) mode. The m/z ratios were as fol-
lows: m/z 843.5[M  +  CH3COO−]  >  843.5 for AS, m/z 
549.4[M  +  CH3COO−]  >  549.3 for cycloastragenol 
(CAG), and 839.5[M + CH3COO−] > 839.5 DIG. The fol-
lowing linear gradient program was applied to the ana-
lyte, using a mobile phase consisting of deionized water 
containing 0.1% acetic acid and 10 mM ammonium ace-
tate (A solution) and acetonitrile (B solution): 0–2  min, 
60:40–10:90; 2–7  min, 10:90; and 7–12  min, 60:40 (A:B 
v/v). The sample injection volume was 5 μL. The flow rate 
was maintained at 0.4 mL/min. The instrumental param-
eters of the MS detector were optimized as follows: cap-
illary voltage, 3000  V; cone voltage, 30 and 50  V (50  V; 
AS and 30 V; DIG and CAG); extractor voltage, 3 V; RF 
lens voltage, 0.2 V; source temperature, 120 °C; desolva-
tion temperature, 350 °C; cone gas flow, 50 L/h; desolva-
tion gas flow, 600 L/h; collision gas flow, 0.15  mL/min; 
collision energy, 5 eV. The linear calibration curves were 
plotted between 0.01, 0.05, 0.1, 0.5, 1, 5, and 10  µg/mL 
(R2  >  0.999). The minimum limit of quantifiable con-
centration was less than 0.01  µg/mL. The following PK 
parameters were calculated: area under the curve (AUC), 
mean residence time (MRT), total body clearance  (CLtot), 
steady-state volume of distribution (Vss), elimination rate 
constant (Kel), biological half-life (T1/2), maximum drug 
concentration time (Tmax), and maximum blood concen-
tration (Cmax) using standard procedures.
Statistical analysis
Results are expressed as mean  ±  SEM. Differences 
between groups were assessed by analysis of variance 
with Tukey’s honest significant difference test or Tukey’s 
test. Survival curves were generated by the Kaplan–Meier 
method, and survival was compared by the log-rank test. 
The PK parameters and blood profiles of AS were com-
pared by the Student’s t test. Differences were considered 
significant for p values <0.05.
Results
Optimizing AS dose on the basis of rat survival 
following bolus injection
The survival rate of the CS-only group was 0% (0/10) 
48 h after reperfusion. The survival rates of the C-1, 2, 5, 
10, and 20 AS-one groups were 0% (0/10), 0% (0/10), 0% 
(0/10), 40% (4/10), and 0% (0/10) 48 h after reperfusion. 
The increase in mortality in the C-20 AS-one group com-
pared to that in the C-10 AS-one group was caused by 
the development of significant metabolic and respiratory 
alkalosis in the former group (Additional file 2: Table S1). 
Moreover, the mean blood pressure (MBP) of the C-10 
AS-one group was more stabilized than that of the CS-
only group 1 and 3 h after reperfusion (Additional file 3: 
Fig. S2). Therefore, we used 10  mg/kg AS-containing 
saline in CS rats in further studies.
AS treatment improves hyperkalemia, shock, 
and metabolic acidosis
K+, CPK, and hematocrit (Hct) in the CS-only group 
were significantly increased compared to those of the 
sham group. In contrast, MBP in the CS-only group was 
significantly decreased compared to that in the sham 
group (Fig.  1). HR, SBP, and DBP in the CS-only group 
were significantly decreased compared to those in the 
sham group (Additional file 4: Table S2). Injured muscle 
edema in the CS-only group was significantly increased 
compared to that in the sham group during the experi-
mental period. In contrast, the fluid resuscitation (i.e., 
C-saline and C-AS) groups had a tendency toward 
increased muscle edema compared to the CS-only group 
(Additional file 5: Fig. S3 and Additional file 6: Table S3). 
The blood gas parameters in the CS-only group indi-
cated severe metabolic acidosis compared to those in the 
sham group (Additional files 7 and 8: Tables S4 and S5). 
By contrast, these changes in the fluid administration 
groups (i.e., C-saline and C-AS groups) were significantly 
improved over those in the CS-only group. Moreover,  K+ 
and CPK levels and blood gas parameters in the C-AS 
group were significantly improved compared to those in 
the C-saline group.
In addition, no adverse effects (i.e., hemolytic action) 
were observed following AS treatment. These would be 
characterized by saponin stimulation; however, hemo-
globin (Hb), mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH), and mean corpuscu-
lar hemoglobin concentration (MCHC) levels were not 
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significantly different among the experimental groups 
(data not shown).
AS treatment improves kidney function in CS
Parameters of kidney function (i.e., BUN, Cre, pH, 
osmotic pressure, urine volume, and GFR levels) are 
shown in Additional files 9 and 10: Tables S6 and S7. 
Acute kidney injury in CS is characterized by acute tubu-
lar necrosis, formation of myoglobin casts, and dilation 
of distal convoluted tubules, followed by myoglobinuric 
nephropathy. Therefore, we evaluated kidney function 
by focusing on the failure of distal convoluted tubules. 
Pathological changes were not observed in the sham 
group. The CS-only group displayed moderate dilatation 
and injury to the tubules after 3 and 24 h of reperfusion 
(Fig.  2a, b). Urine NAG, plasma NAG, and KIM-1/Cre 
ratios in the CS-only group were not significantly dif-
ferent from those in the sham group from 0 to 6 h after 
reperfusion, but were significantly increased after 24  h 
of reperfusion (Fig.  2c–e). Moreover, HO-1 expression 
levels in the CS-only group were significantly increased 
compared to those in the sham group 6 and 24  h after 
reperfusion (Fig.  2f ). By contrast, these changes in the 
CS-only and C-saline groups were significantly improved 
in the C-AS group. In addition, urine pH in the C-AS 
group was significantly improved compared to that in the 
CS-only and C-saline groups (Additional files 9 and 10: 
Tables S6 and S7).
Vascular endothelial damage is attenuated 
by AS‑containing fluid resuscitation via anti‑inflammatory 
effects
Figure  3 indicates that leukocyte activity and filtration 
improved owing to decreased IL-1β and TNF-α levels. 
Muscle MPO activity in the CS-only group was signifi-
cantly increased compared to that in the sham group at 
6 and 24  h. Moreover, blood MPO activity, IL-1β, and 
TNF-α expression were similarly increased at 3, 6, and 
24 h. By contrast, these changes in the C-AS group were 
significantly improved compared to those in the CS-only 
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and C-saline groups. In addition, WBC levels were higher 
in the CS-only, C-saline, and C-AS groups after 3, 6, and 
24 h of reperfusion than those in the sham group were. 
The platelet level in the CS-only group was significantly 
lower than that in the sham group. In contrast, the WBC 
level in the C-AS group tended to be lower than that in 
the CS-only group, and platelet levels were not signifi-
cantly increased compared to those in the CS-only group 
(Additional file 11: Table S8).
Muscle tissue injury is attenuated by avoidance 
of mitochondrial dysfunction and normalization of NO 
generation
NO2− and  NO3− concentrations in injured muscle were 
lower in the CS-only group after 0, 1, and 3 h, and higher 
after 24  h of reperfusion than those in the sham group 
(Fig.  4a, b). This resulted in a temporary decrease in 
eNOS phosphorylation (i.e., activity) and indicated that 
the subsequent increase in eNOS activity and iNOS 
expression were related (Fig.  4c, d). By contrast,  NO2− 
concentrations in the injured muscles of the C-AS group 
were similar to those in the sham group, and those in 
the C-saline group were not significantly different from 
those in the CS-only group. eNOS activity in the C-AS 
group was significantly increased compared to that in the 
other groups after 1 and 3 h of reperfusion. In addition, 
iNOS expression was significantly decreased after 24  h 
of reperfusion. These changes were not observed in the 
C-saline group.
The most important factor in IRI is oxidative stress 
due to mitochondrial dysfunction. We measured cyt 
c leakage into the cytoplasm, JC-1 fluorescence inten-
sity to determine MPT, TBARS to determine oxidative 
stress, and HIF-1α expression to evaluate tissue hypoxia 
(Fig.  5). We observed significantly increased cyt c leak-
age into the cytoplasm and significantly decreased JC-1 
fluorescence intensity in the CS-only group compared to 
those in the sham group at 1, 3, 6, and 24 h (Fig. 5a, b). 
0
2
4
6
8
bl
oo
d 
M
PO
 a
ct
iv
ity
(u
ni
t/m
L
)
0
2
4
6
8
10
12
m
us
cl
e 
M
PO
 a
ct
iv
ity
(u
ni
t/g
 ti
ss
ue
)
0
10
20
30
40
50
60
bl
oo
d 
IL
-1
(p
g/
m
L
)
0
10
20
30
40
50
60
70
bl
oo
d 
T
N
F-
(p
g/
m
L
)
0            1            3            6            24
reperfusion (h)
0            1            3            6            24
reperfusion (h)
*
†
#
#
*
*
*
#
#
#
* *
*
†
#
#
*
*
#
#
* *
*
*
#
#
sham
CS only
C-saline
C-AS
##
a                                                                                      b
c                                                                                      d
Fig. 3 Effect of fluid resuscitation on inflammatory mediators in CS rats. a Muscle MPO activity, b blood MPO activity, c blood IL-1β, and d blood 
TNF-α. White bar sham, black bar CS-only, gray bar C-saline, and shaded bar C-AS. Values represent mean ± SEM (n = 3). #p < 0.05 versus sham group, 
*p < 0.05 versus CS-only group, and †p < 0.05 versus C-saline group (Tukey’s test). CS crush syndrome, MPO myeloperoxidase, IL-1β interleukin-1 
beta, TNF-α tumor necrosis factor-α
Page 8 of 13Murata et al. Ann. Intensive Care  (2017) 7:90 
Simultaneously, the TBARS level in the CS-only group 
was significantly increased after 3 and 6  h of reperfu-
sion (Fig.  5c). In contrast, SOD activity in the CS-only 
group was significantly decreased compared to that in 
the sham group after 3 and 6 h of reperfusion (Fig. 5d). 
Muscle HO-1 and HIF-1α expression in the CS-only 
group were significantly increased compared to those in 
the sham group (Fig. 5e, f ). Accordingly, the RBC levels 
in the CS-only group tended to be higher than those in 
the sham group during the experimental period (Addi-
tional file  12: Table S9). The 50% inhibitory concentra-
tion (i.e., the direct radical scavenging ability) of AS was 
approximately 1/25,000 the value of AA (531.7 ±  190.6 
vs. 0.02 ±  0.01  μM, respectively, Additional file  13: Fig. 
S4). No pathological changes were observed in the sham 
group. There was moderate neutrophil infiltration, mod-
erate edema, mild degeneration, and atrophy in the CS-
only group. Muscle edema and neutrophil infiltration 
were reduced in the C-AS group compared to that in the 
CS-only and sham groups after 6 and 24  h of reperfu-
sion (Additional file 4: Table S2; Additional file 5: Fig. S3) 
(Fig. 5g, h). Overall, in the C-AS group, these pathologies 
improved compared to those in the CS-only and C-saline 
groups, and were similar to those in the sham group.
Blood and urine concentration profile and PK parameters 
of AS
The urinary profile and PK parameters of the C-AS group 
were not significantly different from those of the sham-
AS group, as determined by HPLC methods. A small 
quantity of urinary AS excretion was detected, but did 
not affect PK (data not shown). Therefore, LC–MS/MS 
was performed only for the plasma profile.
We determined the plasma concentration profile and 
PK parameters of AS in sham and CS rats, using LC–MS/
MS methods. CAG was not detected in blood samples. 
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The plasma concentration of the AS profile was similar 
between the sham-AS and C-AS groups 0.083–3 h after 
reperfusion. The profile of the C-AS group was sig-
nificantly lower than that of the sham-AS group 4–24 h 
after administration (Additional file 14: Fig. S5). The PK 
parameters (AUC, MRT, Vss, T1/2, and Tmax) of the C-AS 
group were significantly increased compared to those 
of the sham-AS group, and the  CLtot levels of the C-AS 
group were significantly decreased compared to those of 
the sham-AS group (Table 1).
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Discussion
We performed this study to establish an AS bolus injec-
tion that could be used as a simple therapeutic method 
to treat CS to minimize severe symptoms and improve 
morbidity and mortality [17–20]. An AS bolus injection 
of 10 mg/kg improved the survival rate, but a 20 mg/kg 
AS bolus injection did not because metabolic and res-
piratory alkalosis developed in the 20  mg  kg AS group 
more severely than in the 10 mg/kg AS group (Additional 
file 15: Fig. S6). Therefore, the beneficial AS effect is likely 
“bell-shaped.” However, using fluid resuscitation in addi-
tion to the optimal, 10  mg/kg AS dose is suggested to 
boost efficacy when treating CS.
Kidney injury can cause renal failure, which is a serious 
complication of CS that can result from circulatory shock, 
renal afferent arteriolar vasoconstriction (urinary concen-
tration), increased urinary myoglobin levels, or metabolic 
acidosis (urinary acidity) [21–23]. All of these can cause 
precipitation in distal convoluted tubules and tubular cast 
formation with subsequent tubular obstruction. Myoglo-
bin accumulation has also been shown to cause oxidative 
injury [24, 25]. In these cases, renal replacement therapy 
can improve patient survival. Normal and bicarbonate-
containing saline are recommended as fluids for prevent-
ing hyperkalemia and circulatory shock associated with 
CS. Moreover, maintaining urinary pH above 6.5 can 
prevent intratubular deposition of myoglobin [26]. In the 
present study, administration of fluid containing AS sig-
nificantly improved outcomes compared to administration 
of normal saline. In addition, the C-AS group showed an 
improvement in GFR, urinary pH, and volume compared 
to the CS-only group, indicating that treatment with AS 
protected against renal failure in CS. Interestingly, the 
NAG level in renal tubules, a marker of cytotoxicity, was 
normalized in the C-AS group compared to that in the CS-
only group. Tan et al. [8] demonstrated that AS attenuated 
cystatin C, a kidney dysfunction marker, by suppressing 
nuclear factor kappa B (NF-κB) expression in the kidney of 
rats with IRI-induced acute kidney injury. Generally, HO-1 
is induced by NF-κB, and is cytoprotective following an 
IRI. However, HO-1 protein expression in the C-AS group 
was lower than that in the CS-only and C-saline groups 
in the kidney. The reason for this is likely that HO-1 
protein was not needed following IRI or that HO-1 protein 
expression was inhibited. The improved kidney function 
observed in this study resulted from the former reason. 
We evaluated blood NAG concentration as a new kidney 
function marker. NAG is a lysosomal enzyme in the renal 
proximal tubular epithelium cells that can be released 
when the tubules in the kidney are damaged. Moreover, 
NAG is found in many tissues in the body and has been 
reported previously to be detectable in serum [27]. In the 
clinical situation, urine sample collection from CS patients 
is more difficult than blood sampling because CS patients 
develop anuria. The blood NAG concentration was much 
lower than its urine concentration. Nevertheless, we sug-
gest that blood NAG can be used to assess effectiveness of 
reperfusion at 24 h (Fig. 2d).
CS is known as rescue death because up to 20% of deaths 
occur shortly after extrication [28]. In this study, blood  K+ 
levels in the CS-only group were higher than those in the 
sham group, particularly over time, increasing the risk of 
cardiac arrest in the CS-only group. We previously dem-
onstrated the development of cardiac arrest in CS model 
rats [12]. Interestingly, the decreasing  K+ levels in the 
group administered AS-containing fluid were related to 
the improvement in AKI and low CPK levels during the 
early experimental period, which is possibly related to 
reduced muscle damage. The administration of AS-con-
taining fluid likely normalized hyperkalemia via classical 
mechanisms such as renal excretion of  K+ and cellular 
uptake of  K+. Moreover, our data suggest that AS dramati-
cally improved mitochondrial dysfunction following myo-
cytolysis and had anti-inflammatory effects following IRI. 
First, the administration of AS-containing fluid prevented 
mitochondrial damage by improving mitochondrial mem-
brane potential and mitochondrial outer membrane func-
tion (Fig. 5a, b), because a direct radical scavenging ability 
of AS was not observed (Additional file 13: Fig. S4). Gen-
erally, under ischemic (hypoxic) conditions, mitochondrial 
dysfunction results in ROS generation and NO protects 
mitochondria by acting as an oxygen radical scavenger 
[29]. However, in this study, the anti-radical effects of AS 
activated eNOS and improved the decreased SOD activ-
ity caused by NO. Interestingly, the TBARS level and SOD 
activity in the CS-only group were significantly decreased 
Table 1 Plasma pharmacokinetic parameters of AS in sham and CS rats
Values are presented as the mean ± SEM (n = 3–6)
AUC area under the concentration–time curve, MRT mean residence time, CLtot total body clearance, Vss steady-state volume of distribution, Kel elimination rate 
constant, T1/2 biological half-life, Tmax time to maximum drug concentration, Cmax maximum drug concentration, AS astragaloside-IV, CS crush syndrome
*p < 0.05 versus sham-AS group analyzed by Student’s t test
AUC0–∞h (μg h/mL) MRT (h) CLtot (mL/h) Vss (mL) Kel  (h
−1) T1/2 (h) Tmax (h) Cmax (μg/mL)
Sham-AS 32.9 ± 1.5 2.1 ± 0.0 84.4 ± 4.2 219 ± 41 0.80 ± 0.03 0.88 ± 0.04 1.83 ± 0.33 10.1 ± 0.4
C-AS 36.0 ± 1.3* 2.6 ± 0.2* 78.6 ± 3.4 244 ± 28 0.49 ± 0.02* 1.37 ± 0.03* 2.70 ± 0.11 * 10.3 ± 0.3
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compared to those in the sham group 3 and 6 h after rep-
erfusion. iNOS expression increased and the TBARS level 
decreased in injured muscles 24 h after reperfusion. More-
over, these results demonstrated that increasing HIF-1α 
expression and RBC levels during the experimental period 
generated little NO via the NOS systems because of insuf-
ficient oxygen in the injured muscle. Therefore, radical 
injury in CS was not worsened by iNOS overexpression, 
but by mitochondrial dysfunction and decreased SOD 
activity. Second, AS-containing fluid inhibited leukocyte 
infiltration, as indicated by MPO activity and pathological 
changes due to decreased blood IL-1β and TNF-α levels. 
NO is an important regulatory factor that inhibits leuko-
cyte adhesion [30], expression of intercellular adhesion 
molecules, and p-selectin [31]. We previously reported 
that improving NO consumption attenuated the vascular 
endothelial damage [10, 11, 16]. Therefore, AS may have 
a similar mechanism as we previously reported because 
eNOS was activated in the C-AS group during the early 
phase. Interestingly, the cardio-circulatory dynamics of the 
C-AS group were improved more than those of the sham 
group because edema was improved via attenuated vascu-
lar endothelial damage. In this study, the WBC levels of the 
CS group were markedly decreased after a reaching a max-
imum at 3–24 h. The continued rise of blood MPO activity 
(indicative of leukocyte numbers) suggested an inflam-
matory response, which could subsequently result in an 
immunocompromised state (Fig.  3b; Additional file  12: 
Table S9). According to Gunner [32], sepsis and wound 
infection were found in approximately 50% of cases that 
developed into CS. Therefore, we suggest that improved 
immunosuppression was due to an excessive inflammatory 
response following massive resuscitation with AS-contain-
ing fluid.
CS rats displayed characteristic PK of impaired drug 
metabolism (i.e., inhibition of liver drug-metabolizing 
enzymes and the formation of the third space) [33], but we 
conclude that the high blood concentration of AS (Addi-
tional file 13: Fig. S4) occurred because AS was not renally 
excreted in CS rats [renal clearance  (CLr)/CLtot ratio: 
0.159 ± 0.018/0.180 ± 0.012, as measured by HPLC].
Conclusion
Administration of 10  mg/kg AS-containing fluid led to 
a dramatic improvement in survival following CS owing 
to direct and indirect anti-oxidative effects of AS in the 
kidney, and the prevention of mitochondrial dysfunc-
tion and inflammation owing to AS acting as an NO 
donor in injured muscle (Additional file  15: Fig. S6). 
Moreover, these findings are important with respect to 
the fluid resuscitation limitation of worsening edema by 
fluid resuscitation for prevention of kidney failure and 
cardiac arrest and the promising therapeutic strategy of 
prevention of sepsis by immunosuppression via excessive 
inflammatory response.
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